CN Patent

CN106102734B — 肝内胆汁淤积性疾病的治疗

Assigned to CymaBay Therapeutics Inc · Expires 2019-05-14 · 7y expired

What this patent protects

通过用MBX‑8025或MBX‑8025盐的疗法治疗肝内胆汁淤积性疾病。

USPTO Abstract

通过用MBX‑8025或MBX‑8025盐的疗法治疗肝内胆汁淤积性疾病。

Drugs covered by this patent

seladelpar-lysine (SELADELPAR LYSINE)

Patent Metadata

Patent number: CN106102734B
Jurisdiction: CN
Classification: —
Expires: 2019-05-14
Drug substance claim: No
Drug product claim: No
Assignee: CymaBay Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.